LMNX Luminex

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Company profile

Nachum Shamir
Fiscal year end
IRS number

LMNX stock data



5 May 21
13 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Luminex earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 271.56M 271.56M 271.56M 271.56M 271.56M 271.56M
Cash burn (monthly) 12.62M (positive/no burn) (positive/no burn) (positive/no burn) 7.19M (positive/no burn)
Cash used (since last report) 30.96M n/a n/a n/a 17.64M n/a
Cash remaining 240.6M n/a n/a n/a 253.92M n/a
Runway (months of cash) 19.1 n/a n/a n/a 35.3 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Mar 21 Eric Shapiro Common Stock Grant Aquire A No No 32.76 12,057 394.99K 46,319
12 Mar 21 Eric Shapiro Stock Option Common Stock Grant Aquire A No No 23.09 51,084 1.18M 51,084
12 Mar 21 Nancy Fairchild Common Stock Grant Aquire A No No 32.76 12,515 409.99K 46,707
12 Mar 21 Nancy Fairchild Stock Option Common Stock Grant Aquire A No No 23.09 53,516 1.24M 53,516
12 Mar 21 Collins Charles J. Common Stock Grant Aquire A No No 32.76 14,652 480K 49,503
12 Mar 21 Collins Charles J. Stock Option Common Stock Grant Aquire A No No 23.09 64,868 1.5M 64,868
12 Mar 21 Todd C. Bennett Common Stock Grant Aquire A No No 32.76 16,788 549.97K 47,579
12 Mar 21 Todd C. Bennett Common Stock Payment of exercise Dispose F No No 32.76 2,875 94.19K 30,791
12 Mar 21 Todd C. Bennett Stock Option Common Stock Grant Aquire A No No 23.09 72,976 1.69M 72,976
12 Mar 21 Shamir Nachum Common Stock Grant Aquire A No No 32.76 61,050 2M 240,655

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

84.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 207 195 +6.2%
Opened positions 42 31 +35.5%
Closed positions 30 44 -31.8%
Increased positions 71 74 -4.1%
Reduced positions 71 65 +9.2%
13F shares
Current Prev Q Change
Total value 1.27B 916.07M +39.1%
Total shares 39.91M 39.58M +0.8%
Total puts 275.73K 118.3K +133.1%
Total calls 505.5K 64K +689.8%
Total put/call ratio 0.5 1.8 -70.5%
Largest owners
Shares Value Change
BLK Blackrock 8.3M $264.65M +1.6%
Vanguard 5.44M $173.69M +4.1%
RGM Capital 2.88M $91.97M +6.6%
Dimensional Fund Advisors 1.7M $54.27M -7.7%
Millennium Management 1.59M $50.62M +64.7%
STT State Street 1.53M $49.09M -2.2%
Copeland Capital Management 1.44M $45.78M +3.6%
GS Goldman Sachs 1.21M $38.62M +3.9%
ATAC Neuberger Berman 909.35K $28.76M -5.1%
AMP Ameriprise Financial 795.22K $25.37M +2.6%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -634.16K EXIT
Millennium Management 1.59M +623.33K +64.7%
Balyasny Asset Management 486.5K +486.5K NEW
Ophir Asset Management Pty 0 -434K EXIT
Renaissance Technologies 226.9K -430.34K -65.5%
Arrowstreet Capital, Limited Partnership 0 -393.78K EXIT
Acadian Asset Management 769.29K -384.11K -33.3%
IVZ Invesco 659.51K +350.83K +113.7%
Eagle Asset Management 425.67K +251.18K +144.0%
BAM Brookfield Asset Management 250.8K +250.8K NEW

Financial report summary

Management Discussion
  • This Quarterly Report on Form 10-Q contains statements that are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide our current expectations of forecasts of future events. All statements other than statements of current or historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy, impact of the reimbursement landscape, products including ARIES, VERIGENE, NxTAG, Muse, Guava, easyCyte, InCyte, Amnis, ImageStream, FlowSight and CellStream, assay sales, consumable sales patterns and bulk purchases, budgets, system sales, anticipated gross margins, liquidity, cash flows, projected costs and expenses, taxes, deferred tax assets, regulatory approvals or the impact of laws or regulations applicable to us, plans and objectives of management for future operations, and impact of prior acquisitions or future acquisitions, integration and the expected benefit of our acquisitions are all forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “projects,” “will” and similar expressions as they relate to us, are intended to identify forward-looking statements. These statements are based on our current plans and actual future activities, and our financial condition and results of operations may be materially different from those set forth in the forward-looking statements as a result of known or unknown risks and uncertainties, including, among other things:
  • •risks and uncertainties related to our proposed acquisition by DiaSorin S.p.A;
Content analysis
H.S. junior Avg
New words: absence, agree, agreed, analyst, antitrust, asserting, attract, audit, azioni, bifurcated, billion, BNP, breach, bridge, building, cancelled, categorical, CE, certificate, Chancery, choice, Committee, confidence, constant, consummated, consummation, coupled, court, cumulative, customary, Delaware, deny, description, DGCL, Diagonal, DiaSorin, director, discourage, dissenting, district, diversion, doctrine, duty, easyCheck, Economy, endorsement, exclusive, exhibit, expiration, expired, fee, fiduciary, firm, FlowCellect, flu, forum, French, fullest, GuavaSoft, hand, home, inapplicable, INSPIRE, investor, Italy, judicial, loan, located, LumAvidin, LX, MagPlex, Mark, matter, Mediobanca, MicroPlex, Ministry, mortgage, mutually, Nexin, organized, outlook, owed, owner, Parent, proceeding, prove, purport, raw, receipt, recovery, relationship, Republic, resolution, retain, retrospective, RSV, SD, SeroMAP, Simplifying, slightly, societ, solicit, SpeedBead, sponsorship, superior, surviving, SYNCT, syncytial, syndicate, text, thereunder, timeframe, Topic, trademark, unclear, unenforceable, UniCredit, ViaCount, waiting, wholly, writing, wrote, xPONENT, XYP
Removed: absolute, accurate, accurately, achieve, acid, added, adding, addressed, adhere, advantage, affordable, aid, Alex, amplification, analyte, analyze, analyzed, animal, antibiotic, applied, approved, architecture, area, assure, attaching, automate, automation, Azar, back, bacteria, barcode, batch, began, begin, benchtop, bind, biochemical, biomarker, blood, bonding, bringing, capture, captured, care, cartridge, CDF, ceasing, cell, centered, certified, CFR, chemistry, claimed, cleared, CLIA, clinically, Clostridium, coated, collectability, collected, collecting, color, colored, combine, Commissioner, commitment, compare, competing, complex, complexity, computer, conclusion, conclusive, conducted, congregation, continuance, contrast, correcting, Cosmetic, counterparty, counting, create, credit, culture, customizable, customizing, cytometer, database, dating, declaration, deducted, delaying, demonstrate, detail, detect, detected, detection, diagnosing, difficile, digital, discovery, discretion, displayed, dissolving, distinctive, distinctly, distinguish, distraction, distribute, DNA, doubtful, dye, efficient, efficiently, effort, EMD, emitting, ensuring, enteric, enzymatic, Epidemic, established, evidence, exercise, expensed, extraction, false, family, FDCA, flexibility, flexible, fluorescence, fluorescent, footprint, foundation, functional, gain, Gen, generate, genetic, geographic, gold, GPP, halt, healthcare, highly, history, hospital, hour, hydrogen, identity, illumination, imaging, immunologic, important, independent, individual, inexpensive, infection, informed, injected, innovative, inspection, instrumentation, interested, interface, involved, IRS, isoC, isoG, issue, IVD, labeling, labor, laser, leading, Likewise, magnetic, mandatory, maximum, MDx, meaningful, medicine, menu, met, microarray, microcapillary, microscopy, microsphere, microtiter, Millipore, mixed, mixture, moderate, modular, module, multiplex, NanoGrid, nanoparticle, nasopharyngeal, natural, naturally, newly, noted, nucleic, nucleotide, occurring, operator, optimized, ordered, outbreak, outweigh, pair, particle, patient, pattern, paying, performed, performing, permit, permitting, personalized, pharmacogenetic, plate, pooled, population, posed, positive, precision, prescribe, previously, pricing, probe, processing, produce, professional, proper, prospective, protein, Protocol, purification, purpose, qualitative, reclassified, recording, regimen, relief, remeasured, remotely, reporter, represent, reputation, researcher, resistance, restatement, restating, revised, revocation, revoke, revoked, room, RP, ruling, save, scalable, scanning, scientific, Secretary, section, seek, segment, select, sensitivity, sequential, signal, signature, simple, simultaneously, single, software, solution, spatial, specificity, spectrum, speed, STAT, stored, stream, supplier, supportable, surface, suspected, suspending, swab, syndromic, synthetic, targeted, technical, temporary, terminated, tested, therapeutic, threat, today, tracking, traditional, transition, tube, type, typically, ultimate, unapproved, unavailable, Universal, utilize, versatile, viability, viewed, vitro, waived, wide, widespread, yeast